Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Pioneering technique shows promise for new medical diagnostics, targeted drug delivery

Pioneering technique shows promise for new medical diagnostics, targeted drug delivery

Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules--the enzymes. [More]
Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a powerhouse team of researchers at the University of North Carolina at Chapel Hill has revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them - all while showing signs that the rest of the body would be spared toxic side effects. [More]
Asian manufacturers wear testing offered by Lucideon & Hong Kong standards and testing center collaboration

Asian manufacturers wear testing offered by Lucideon & Hong Kong standards and testing center collaboration

Lucideon, the international materials technology company, has announced that it has extended its collaboration agreement with the Hong Kong Standards and Testing Centre (STC) to include wear testing of orthopaedic hip and knee implants. [More]
Halozyme closes $150 million royalty-backed debt transaction

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta. [More]
AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology. [More]
Incidence of childhood myopia has more than doubled over last 50 years among American children

Incidence of childhood myopia has more than doubled over last 50 years among American children

The largest study of childhood eye diseases ever undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years. The findings echo a troubling trend among adults and children in Asia, where 90 percent or more of the population have been diagnosed with myopia, up from 10 to 20 percent 60 years ago. [More]
Amorphous iron nanoparticles have potential to kill tumor cells

Amorphous iron nanoparticles have potential to kill tumor cells

Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies. [More]
Artificial pancreas moves closer to becoming a reality

Artificial pancreas moves closer to becoming a reality

As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion--known as the "artificial pancreas"--moves closer to becoming a reality. [More]
Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity. [More]
GBI Research says COPD therapeutics pipeline lacks innovation

GBI Research says COPD therapeutics pipeline lacks innovation

Analysis from business intelligence provider GBI Research - Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation - states that while currently-available drugs aim to manage the frequency and severity of symptoms associated with COPD, none have been shown to modify long-term disease progression. [More]
Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

If you're scared of the dentist's needles you're not alone - but new research means you might not have to put off that appointment again. A study published in Colloids and Surfaces B: Biointerfaces reveals how the dentist could give you anesthetic using a tiny electric current instead of a needle. [More]
Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor. [More]
University of Copenhagen researchers develop new cell line to investigate brain drugs

University of Copenhagen researchers develop new cell line to investigate brain drugs

Researchers from the Department of Pharmacy at the University of Copenhagen have developed a cell line, which may be used to investigate new drugs and help predict whether they are able to enter the brain. [More]
Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists are joining forces with Harvard University experts to help revolutionize the treatment of lung diseases -- the delivery of nanomedicine deep into places otherwise impossible to reach. [More]
New approach to package dual or more mixtures into a single capsule may boost drug efficiency

New approach to package dual or more mixtures into a single capsule may boost drug efficiency

Researchers have developed a speedy, controllable way to get two or more ingredients into the same tiny capsule and only have them mix when triggered by a signal like vibrations or heat. [More]
Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules. [More]

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI). [More]
New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

With a median survival rate of just five to seven years, Mantle Cell Lymphoma (MCL) is considered the most aggressive known blood cancer -- and available therapies are scarce. Three thousand Americans are diagnosed with MCL every year, and despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research. [More]
First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

First patient enrolled in Phase 3 efficacy trial of CAM2038 for opioid dependence

Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration. [More]
Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

Discovery Laboratories initiates AEROSURF phase 2b clinical trial in premature infants with RDS

Discovery Laboratories, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has initiated its AEROSURF phase 2b clinical trial in premature infants 26 to 32 weeks gestational age (GA) receiving non-invasive nasal continuous positive airway pressure (nCPAP) for respiratory distress syndrome (RDS). [More]
Advertisement
Advertisement